C
Carl-Magnus Svahn
Publications - 4
Citations - 712
Carl-Magnus Svahn is an academic researcher. The author has contributed to research in topics: Heparin & Basic fibroblast growth factor. The author has an hindex of 3, co-authored 4 publications receiving 703 citations.
Papers
More filters
Journal ArticleDOI
Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules.
Pnina Bashkin,Susan R. Doctrow,Michael Klagsbrun,Carl-Magnus Svahn,Judah Folkman,Israel Vlodavsky +5 more
TL;DR: It is suggested that ECM storage and release of bFGF provide a novel mechanism for regulation of capillary blood vessel growth and its displacement by heparin-like molecules and/or HS-degrading enzymes may elicit a neovascular response.
Journal ArticleDOI
Importance of size and sulfation of heparin in release of basic fibroblast growth factor from the vascular endothelium and extracellular matrix.
Rivka Ishai-Michaeli,Carl-Magnus Svahn,Michael J. Weber,Tova Chajek-Shaul,Gil Korner,Hans Peter Ekre,Israel Vlodavsky +6 more
TL;DR: Structural requirements were identified for release of 125I-bFGF bound to low-affinity sites on the surface of vascular endothelial cells and low-sulfate oligosaccharides were less effective releasers of bFGF as compared to medium- and high-Sulfate fractions of the same size oligosACcharides.
Patent
Novel heparin derivatives and process for the preparation thereof
TL;DR: In this article, the use of new heparin derivatives from bovine or porcine heparins which have a molecular weight equal to or larger than the standard hepin, show a sulfur content which is equal to the starting hepin or at least 13 % w/w, have an anticoagulant activity in the anti-FXa assay of less than 10 % of the standard Heparin it was made from, and show a ratio of APTT activity over anti- FXa activity of 3-35, showed a reduced prolongation of
Patent
Heparin derivatives for treatment of angina pectoris
TL;DR: In this paper, the use of new heparin derivatives from bovine or porcine heparins which have a molecular weight equal to or larger than the standard hepin, show a sulfur content which is equal to the starting hepin or at least 13% w/w, have an anticoagulant activity in the anti-FXa assay of less than 10% of the standard Heparin it was made from, show a ratio of APTT activity over anti- FXa activity of 3-35, and show a reduced prolongation of